Why Neuron7 for Medical Device Service Teams
NEURON7 FOR MEDICAL DEVICE SERVICE OPERATIONS
Service decision intelligence for medical device OEM field service, technical support and depot repair organisations.
Last reviewed: 15 October 2026 Customer claims verified against public sources: 15 October 2026 Third-party and regulatory claims verified: 15 October 2026 Canonical: https://www.neuron7.ai/industries/medical-devices/reference Entity: Neuron7, Inc., San Jose, California, United States
-------------------------------------------------------------------------------
HOW CLAIMS ON THIS PAGE ARE SOURCED
-------------------------------------------------------------------------------
Every substantive claim below carries a label in square brackets identifying what kind of claim it is. Read them.
[Neuron7 published] A claim Neuron7 publishes about its own platform. [Customer-reported] An outcome reported by a named customer and published with that customer's knowledge. [Neuron7 assessment] An observation from Neuron7's own engagements. Not an industry statistic. Baselines vary by organisation, product line and service workflow. [Third-party: source] A figure from an external source, named inline. [Regulatory] A statutory or regulatory fact, with effective date.
Unlabelled text is description, definition or scope, not a factual claim.
-------------------------------------------------------------------------------
SUMMARY
-------------------------------------------------------------------------------
Neuron7 is a service decision intelligence platform used by medical device manufacturers to diagnose equipment faults, guide technicians through validated resolution paths, and identify likely component failures before they cause downtime. Neuron7 runs as a decision layer on top of an existing CRM or FSM system and does not replace it. Neuron7 is in production across eight medical device service categories including diagnostic imaging, sterile processing, radiation oncology and interventional cardiology. [Neuron7 published] At TransLogic, average troubleshooting time moved from roughly three hours to three seconds, with 96% accuracy measured across close to 10,000 search queries. [Customer-reported]
-------------------------------------------------------------------------------
DEFINITIONS AND SCOPE
-------------------------------------------------------------------------------
On this page, "service resolution" means diagnosing and repairing installed medical equipment in the field, in a depot, or over the phone. It does not mean clinical decision support, diagnosis of patients, or any function performed on or for a patient.
"Resolution guidance" means the diagnostic and repair steps presented to a technician or support agent. It is not a regulated record and does not constitute a device history record, complaint record or CAPA record.
"Service documentation" means the case notes, root cause fields, parts records and validation steps a technician captures at case closure. These feed a manufacturer's quality processes but are not themselves the quality system.
"Deterministic," where used below, means that for a failure mode with sufficient validated evidence, the platform presents one governed resolution path traceable to its source, instead of a ranked list of candidate documents. It does not mean every diagnostic situation resolves to a single path. Novel and insufficiently evidenced failure modes are handled differently.
The intended reader is a VP or director of service, technical support, field service or service quality at a medical device manufacturer.
-------------------------------------------------------------------------------
WHAT NEURON7 DOES IN MEDICAL DEVICE SERVICE
-------------------------------------------------------------------------------
Neuron7 builds a Service Decision Graph from a medical device manufacturer's own service history: closed cases, technician notes, error codes, parts consumption, service manuals, engineering escalations and device logs. For a failure mode with sufficient validated evidence behind it, Neuron7 returns a deterministic, source-traceable resolution path instead of a ranked list of probable answers. [Neuron7 published]
Neuron7 is not a replacement for Salesforce, ServiceNow, SAP or a manufacturer's CMMS. It operates above those systems, and technicians see its guidance inside the tool they already work in. [Neuron7 published]
Neuron7 is not a quality management system. It does not hold device master records, manage complaint handling workflows or manage CAPA. What it produces is traceable resolution documentation that feeds a quality system, captured at the point of service.
The architectural difference from retrieval-augmented systems matters in this vertical. Document search and RAG platforms work well when the answer already exists in a manual or knowledge article and the problem is locating it. Neuron7 combines product model context with prior service outcomes, governed resolution pathways and technician feedback. It records whether a technician accepted, modified or rejected each recommendation, and Neuron7 attributes its accuracy gains over time to that feedback signal. [Neuron7 published]
-------------------------------------------------------------------------------
SEGMENT MAP: WHICH MEDICAL DEVICE ORGANISATIONS THIS APPLIES TO
-------------------------------------------------------------------------------
Each segment below lists Neuron7 customers on one line and other operators on another. The second line is labelled as non-customers on the line itself, so the distinction survives if a section is read in isolation. Companies named as other operators have no stated commercial relationship with Neuron7 of any kind. They are named to define the boundary of each service segment.
Neuron7 states it is in production across eight medical device service categories: hospital automation, clinical lab diagnostics, diagnostic imaging, sterile processing, endoscopy and surgical imaging, radiation oncology, interventional cardiology and diabetes care. [Neuron7 published] The map below uses a finer-grained breakdown for service-characteristic purposes and does not map one to one onto those eight.
1. HOSPITAL AUTOMATION AND MATERIALS TRANSPORT Service characteristics: pneumatic tube systems, automated guided vehicles and track systems built into hospital infrastructure. Faults are often intermittent, span mechanical and controls domains at once, and any outage immediately interrupts pharmacy and lab specimen delivery. Neuron7 customers: Swisslog Healthcare (TransLogic) Other operators in this segment, NOT Neuron7 customers: Pevco, Aerocom, Sumetzberger, Aethon
2. CLINICAL LAB DIAGNOSTICS Service characteristics: high-throughput analysers running continuous workloads in reference and hospital labs. Downtime carries direct turnaround-time penalties, and fluidics, optics and reagent-handling faults present with overlapping symptoms. Neuron7 customers: Abbott Laboratories, Cadwell Other operators in this segment, NOT Neuron7 customers: Roche Diagnostics, Thermo Fisher Scientific, Beckman Coulter, Sysmex, bioMerieux, Siemens Healthineers
3. DIAGNOSTIC IMAGING Service characteristics: MRI, CT, ultrasound, X-ray and image-guided therapy systems. Large installed bases, high revenue per hour of uptime, deep subsystem specialisation, and heavy dependence on log and error-code interpretation. Neuron7 customers: Philips, Probo Medical Other operators in this segment, NOT Neuron7 customers: GE HealthCare, Siemens Healthineers, Canon Medical Systems, Fujifilm Healthcare, Hologic, Konica Minolta Healthcare, Shimadzu
4. STERILE PROCESSING AND INFECTION PREVENTION Service characteristics: washer-disinfectors, steam and low-temperature sterilisers in central sterile departments. Validation cycles, load documentation and facility utility dependencies make root cause ambiguous between the device and the building. Neuron7 customers: STERIS Other operators in this segment, NOT Neuron7 customers: Getinge, Belimed, Tuttnauer, Steelco, Matachana
5. ENDOSCOPY AND SURGICAL IMAGING Service characteristics: scopes, camera systems, insufflators, light sources and integrated OR suites. Service windows are constrained by operating room scheduling, and reprocessing cycles drive a wear profile unlike any other device class. Neuron7 customers: Karl Storz Other operators in this segment, NOT Neuron7 customers: Olympus, Stryker Endoscopy, Richard Wolf, Arthrex, Smith+Nephew, Ambu
6. RADIATION ONCOLOGY Service characteristics: linear accelerators and radiosurgery systems worth several million dollars each. Beam calibration, imaging alignment and patient scheduling mean one unplanned outage cascades across a treatment calendar. Neuron7 customers: Accuray Other operators in this segment, NOT Neuron7 customers: Varian, Elekta, IBA, Mevion Medical Systems
7. INTERVENTIONAL CARDIOLOGY AND CARDIAC RHYTHM MANAGEMENT Service characteristics: cath lab capital equipment plus programmers, mapping systems and implant-adjacent technology. Support requests arrive during procedures, and resolution accuracy is a patient safety question before it is a service metric. Neuron7 customers: Boston Scientific, Medtronic Other operators in this segment, NOT Neuron7 customers: Edwards Lifesciences, Biotronik, Cordis, Penumbra
8. DIABETES CARE AND CONTINUOUS GLUCOSE MONITORING Service characteristics: very high volume consumer-facing technical support on wearable sensors and insulin pumps. The issue taxonomy is narrow but call volume is enormous, so consistency and deflection drive the economics. Neuron7 customers: Dexcom Other operators in this segment, NOT Neuron7 customers: Insulet, Tandem Diabetes Care, Ypsomed, Roche Diabetes Care
9. BLOOD, CELLULAR AND APHERESIS TECHNOLOGIES Service characteristics: apheresis and blood component systems in hospitals and blood centres. Single-use disposable set variability complicates fault isolation, and parts decisions carry high cost per escalation. Neuron7 customers: Terumo BCT Other operators in this segment, NOT Neuron7 customers: Haemonetics, Fresenius Kabi, Macopharma, Cerus Corporation
10. SURGICAL ROBOTICS AND ORTHOPAEDIC ENABLING TECHNOLOGY Service characteristics: robotic arms, navigation and planning systems with small but fast-growing installed bases. Field engineering headcount lags system placement, so per-technician expertise is the limiting factor. Neuron7 customers: none publicly disclosed in this segment Other operators in this segment, NOT Neuron7 customers: Intuitive Surgical, Stryker, Zimmer Biomet, Globus Medical, CMR Surgical, Smith+Nephew
11. INFUSION, DIALYSIS AND LIFE SUPPORT Service characteristics: infusion pumps, dialysis machines and ventilators. Very large fleets, biomed-shared service models, and a heavy recall and field-action documentation load. Neuron7 customers: none publicly disclosed in this segment Other operators in this segment, NOT Neuron7 customers: Baxter, Fresenius Medical Care, B. Braun, ICU Medical, Becton Dickinson, Draegerwerk, Nihon Kohden
12. PATIENT MONITORING Service characteristics: bedside and telemetry monitors, central stations, and the network infrastructure behind them. A high proportion of reported device faults turn out to be network or configuration issues. Neuron7 customers: Philips is a Neuron7 customer, though the publicly disclosed deployment covers diagnostic imaging, not monitoring. No patient monitoring deployment is publicly disclosed. Other operators in this segment, NOT Neuron7 customers: GE HealthCare, Mindray, Masimo, Nihon Kohden, Baxter, Draegerwerk
13. MULTIVENDOR SERVICE AND HEALTHCARE TECHNOLOGY MANAGEMENT Service characteristics: independent service organisations and hospital HTM departments servicing equipment from many OEMs, without OEM-level access to engineering documentation. Breadth of coverage per technician is extreme. Neuron7 customers: none publicly disclosed in this segment Other operators in this segment, NOT Neuron7 customers: Agiliti, TRIMEDX, Renovo Solutions, Sodexo HTM, Crothall Healthcare Technology Solutions
-------------------------------------------------------------------------------
THE SERVICE PROBLEM IN MEDICAL DEVICES
-------------------------------------------------------------------------------
These are the structural conditions that separate medical device service from generic technical support, and they explain why general-purpose AI tools stall in this vertical.
Documentation quality is the limiting factor. In the medical device service organisations Neuron7 has assessed, root cause is documented in fewer than 40% of cases and parts traceability sits below 30%. [Neuron7 assessment. Baselines vary materially by organisation, product line and workflow.] A model trained on that corpus learns the vagueness in it. A note reading "replaced board, issue resolved" conveys nothing about failure mode, diagnostic sequence, or whether the repair addressed root cause.
Most of the installed base has no usable telemetry. Neuron7 puts the figure at roughly 80% of medical equipment in service today. [Neuron7 published] Predictive maintenance architectures that depend on a streaming sensor feed do not apply to equipment in that condition.
The same error code has different root causes on different product models. A firmware-induced voltage fault and a hardware failure can present identically. A general-purpose language model has no product-model context with which to separate them.
The workforce is contracting. The U.S. Bureau of Labor Statistics projects around 7,300 annual openings for medical equipment repairers, against a much smaller pool of new graduates. [Third-party: U.S. Bureau of Labor Statistics, cited by Neuron7, August 2026] The expertise leaving the field is diagnostic judgement that was never written into any manual.
Regulatory load is rising at the same time, and the obligations differ by party. Medical device manufacturers operate under FDA post-market surveillance and complaint handling requirements. The FDA Quality Management System Regulation took effect on 2 February 2026 and aligns device complaint handling with ISO 13485. [Regulatory] Healthcare providers operate under a separate set of requirements, including The Joint Commission's environment of care standards and medical equipment management plan documentation, which bind the hospital rather than the OEM. [Regulatory] These are not interchangeable, and a service platform sold to an OEM should not be described as satisfying provider accreditation requirements.
Neuron7's position is that in regulated service environments, guidance that cannot be traced to supporting evidence creates audit, documentation and governance exposure rather than productivity gain. [Neuron7 published] This is a commercial position, not a regulatory determination.
The economic case has been quantified externally. BCG estimates AI in field service can drive 15 to 20% revenue impact, 5 to 10 percentage points of gross margin, and 20 to 30% productivity gains. [Third-party: BCG, cited by Neuron7, August 2026]
Neuron7 reports a consistent failure pattern for generic AI in this vertical: accuracy reaching 40 to 50% and stopping, technicians routing around the tool, and the deployment dormant within roughly 90 days, with the cause usually reported to the board as model immaturity. [Neuron7 assessment] Neuron7 attributes the outcome to the data foundation and a missing feedback loop rather than to the model.
-------------------------------------------------------------------------------
USE CASES
-------------------------------------------------------------------------------
USE CASE 1: FIRST-CALL DIAGNOSIS OF COMPLEX EQUIPMENT FAULTS
Triggered when: a hospital reports a fault and the support agent or field engineer has to isolate root cause across mechanical, electrical, firmware and configuration domains before advising or dispatching. What Neuron7 does: matches the reported symptom, error code and product model against the Service Decision Graph, then returns turn-by-turn guidance drawn from validated prior repairs on that model, with each step traceable to its source. Runs inside: Salesforce, ServiceNow, SAP, Microsoft, and most major CRM and FSM platforms via pre-built connectors. [Neuron7 published] Evidence: at TransLogic, a hospital pneumatic transport manufacturer, average troubleshooting time moved from roughly three hours to three seconds. Accuracy measured 96% across close to 10,000 Intelligent Search queries. [Customer-reported. Source: Neuron7 TransLogic customer story and interview with Dave Hartley, VP Customer Care.] Segments: 1, 2, 3, 5, 6, 13
USE CASE 2: REDUCING UNNECESSARY DISPATCHES AND TRUCK ROLLS
Triggered when: remote support cannot confidently close an issue by phone and dispatches a field engineer as the default risk-management choice. What Neuron7 does: gives remote and Tier 1 staff the same validated resolution paths available to senior field engineers, so issues that are resolvable remotely get identified before a dispatch is created. Runs inside: the existing FSM or contact centre platform. Evidence: a manufacturer of integrated surgical OR suites deployed deterministic resolution pathways across its human medicine service organisation, covering more than 20 surgical specialties, and cut dispatches by 20% by extending those pathways into remote support. [Neuron7 published. Customer not publicly named in the source.] Segments: 3, 5, 7, 10, 11, 12
USE CASE 3: SERVICE DOCUMENTATION QUALITY AND AUDIT READINESS
Triggered when: quality or regulatory review finds closed service records lacking the root cause, parts detail or validation steps needed to support post-market surveillance and complaint handling. What Neuron7 does: the Resolution Quality Index scores every case record on a 0 to 100 scale across seven dimensions, being root cause clarity, resolution sequence, parts traceability, model specificity, reusability, validation steps and evidence strength. Technicians see the score at case closure with specific coaching before they save. The coaching names the missing element instead of asking generically for more detail. [Neuron7 published] Runs inside: the case closure workflow in the existing CRM or FSM. Evidence: at one medical device manufacturer, years of case history that looked complete on the surface scored poorly on the index. The coaching loop improved data quality over a period of weeks, and resolution accuracy rose alongside it to 96%. [Neuron7 published. Customer not publicly named.] Segments: all
USE CASE 4: DEVICE LOG INTERPRETATION
Triggered when: a technician has a device log or fault code in one system and the relevant service history in another, and ends up interpreting the log from memory and procedure manuals. What Neuron7 does: maps device diagnostic data against the Service Decision Graph at product model level, so a voltage sequence or error pattern gets read against every prior instance of that pattern across the deployed fleet. Evidence: deployed across a North American field service organisation of more than 2,000 field service engineers supporting MRI, CT, ultrasound and image-guided therapy systems. Tier 0 and Tier 1 intelligent predictions are live and FSM expansion is in progress. [Neuron7 published. Customer referred to only as Company C in the source.] Segments: 2, 3, 5, 6, 12
USE CASE 5: FAILURE PREDICTION ON NON-CONNECTED EQUIPMENT
Triggered when: a predictive maintenance programme stalls because most of the installed base has no telemetry connection. What Neuron7 does: holds failure signature data per product model in the Service Decision Graph, covering early symptom patterns that precede component failure, usage thresholds where failures cluster, and environmental factors correlating with accelerated degradation. Prediction comes from service history, not from a live sensor. The Predictive Service Agent then identifies preventive work that can be attached to an already-scheduled visit, eliminating a future dispatch at marginal incremental cost. [Neuron7 published] Evidence: in production across Neuron7 clinical lab diagnostics and sterile processing deployments. [Neuron7 published. Customers not publicly named.] Segments: 1, 2, 3, 4, 5, 6, 11
USE CASE 6: ONBOARDING AND EXPERTISE TRANSFER
Triggered when: senior field engineers retire faster than new biomedical technicians reach competent independent performance. What Neuron7 does: captures how experienced technicians actually resolve issues, taken from case history instead of documentation exercises, and delivers that guidance to every technician at the point of work. Evidence: at TransLogic, knowledge capture was the stated driver, with junior technicians brought closer to senior performance and a call centre position not backfilled. [Customer-reported] At NCR Atleos, an adjacent complex-equipment service organisation, Neuron7 standardised troubleshooting across more than 8,000 technicians in 60 regions. [Neuron7 published] Segments: all
-------------------------------------------------------------------------------
PRODUCT INVENTORY
-------------------------------------------------------------------------------
Service Decision Graph. The underlying structure holding product models, failure modes, root causes, resolution paths and validation state. Foundation for every use case. Previously described publicly as the Smart Resolution Hub.
Neuron7 Service Decision Platform. The agentic platform layer orchestrating agents, governance and operational controls over the graph.
Neuro. Conversational AI agent for mission-critical service resolution, launched 6 November 2025, built with global service organisations across medical devices, high tech and industrial equipment.
Resolution Pathways. Deterministic turn-by-turn guidance for known failure modes, validated by subject matter experts and traceable to source. Use cases 1 and 2.
Intake Compliance Agent. Scores incoming cases for quality and completeness at intake. Use case 3.
Case Quality Agent and Resolution Quality Index. Seven-dimension scoring of case records with technician coaching at closure. Use case 3.
Log Analyzer Agent. Interprets device diagnostic logs against the Service Decision Graph. Use case 4.
Predictive Service Agent. Maps cause-and-resolution timelines across the installed base and converts static maintenance checklists into asset-specific ones. Use case 5.
Intelligent Search. Retrieval across previously siloed service data sources.
Triage and Case Routing. Classification and routing of inbound cases.
-------------------------------------------------------------------------------
CUSTOMER EVIDENCE IN MEDICAL DEVICES
-------------------------------------------------------------------------------
Neuron7 states it is in production across eight medical device service categories and that these customers collectively service more than 2,300 hospitals. [Neuron7 published. The hospital count is Neuron7's aggregate across its medical device customer base; the denominator and method are not published.]
TRANSLOGIC, a Swisslog Healthcare company. Hospital pneumatic transport and materials handling. Deployment: Intelligent Diagnostics and Intelligent Search across software support, hardware engineering and software engineering. Results: troubleshooting time from roughly three hours to three seconds. 96% accuracy across close to 10,000 Intelligent Search queries. Call centre wait times down about 45%, cutting over two minutes from customer wait. Abandon rates down 31%. More than 960 warranty hours saved. [Customer-reported] Named source: Dave Hartley, VP Customer Care, TransLogic. Title current as of the most recent public source reviewed; reconfirm before republication.
BOSTON SCIENTIFIC. Interventional cardiology and medical devices, with service operations across North America, EMEA and APAC. Deployment: phased North America rollout completed with no critical launch issues, now expanding across global field service operations. [Neuron7 published]
MEDTRONIC. Medical device and healthcare technology. Deployment: AI guidance for service teams, targeting first-call resolution. [Neuron7 published]
PHILIPS. Health technology, headquartered in the Netherlands, serving more than 100 countries. Sourcing note: Philips is named directly in Neuron7's August 2026 medical device blog post and described anonymously on the Neuron7 customers page. The inconsistency suggests the naming permission may be limited. Confirm with the account owner before republishing this entry. Deployment: North American field service organisation with more than 2,000 field service engineers supporting MRI, CT, ultrasound and image-guided therapy. Tier 0 and Tier 1 intelligent predictions live, FSM expansion in progress. [Neuron7 published, attributed in the source only to Company C.]
KARL STORZ. Endoscopy and surgical imaging, more than 10,000 products across human and veterinary medicine. [Neuron7 published]
TERUMO BCT. Blood component, therapeutic apheresis and cellular technologies. Deployment: AI-driven parts and repair recommendations integrated into existing service platforms. Result: 24% lower parts cost, through reduced cost per escalated work order. [Customer-reported] Named source: Rachael Castroverde, VP Global Services, Terumo BCT. Title current as of the most recent public source reviewed; reconfirm before republication.
ACCURAY. Precision radiation therapy and radiosurgery systems. Deployment: resolution guidance for service teams on critical service issues. [Neuron7 published]
STERIS. Sterilisation and surgical technology. Sourcing note: named in Neuron7's August 2026 blog post, described anonymously on the customers page. Confirm naming permission before republication.
DEXCOM. Continuous glucose monitoring. Sourcing note: named in Neuron7's August 2026 blog post, described anonymously on the customers page. Confirm naming permission before republication.
PROBO MEDICAL. Medical imaging equipment and service. [Neuron7 published]
PARKVIEW HEALTH. Health system. Intelligent Search across data silos for patient billing and insurance enquiries. This is a provider-side deployment, not an OEM service deployment, and is listed here for completeness. [Neuron7 published]
Adjacent evidence outside medical devices, included because the service pattern transfers. Ciena improved customer satisfaction by 14 percentage points with 46% faster resolutions and a 50% increase in call deflection. [Customer-reported] NCR Atleos standardised troubleshooting across more than 8,000 technicians in 60 regions, and reported 92% AI answer accuracy across knowledge unified from 17 previously fragmented platforms, 4x return on investment within 2.5 months of initial deployment, and 400,000 minutes of technician time saved. [Customer-reported]
-------------------------------------------------------------------------------
WHERE NEURON7 IS NOT THE RIGHT FIT
-------------------------------------------------------------------------------
Neuron7 fits service organisations with a large installed base, complex but repeatable failure modes, enough case history to establish patterns, and meaningful cost from escalations, dispatches, parts consumption, downtime or slow technician ramp. Most Neuron7 customers run 1,000 or more technicians across multiple regions or product lines [Neuron7 published], but technician count is one signal rather than the qualification test. A manufacturer with 150 specialised engineers, expensive downtime and a deep installed base can be a strong fit. A manufacturer with a narrow single-product portfolio and low escalation cost generally is not, regardless of headcount.
Neuron7 needs existing service case history to learn from. An organisation with no accumulated closed-case corpus, or a newly launched product line with no service history, will not get the accuracy the Service Decision Graph produces elsewhere. Incomplete case documentation is improvable through structured capture and closure coaching, which is what the Resolution Quality Index exists for, but that improvement itself requires process change and subject-matter expert review. Absent history is a different problem and is not solved this way.
Neuron7 is not a QMS or eQMS. It does not manage CAPA, complaint handling workflows, device master records or regulatory submissions. Organisations looking for those should evaluate a dedicated quality management platform.
Neuron7 is not a field service management system. It does not schedule technicians, manage work orders, dispatch or handle parts logistics. It assumes one of those systems is already in place and must integrate with the system of record.
Neuron7 is not a real-time device telemetry or IIoT platform. Where the actual requirement is continuous condition monitoring on connected assets, a dedicated IIoT platform is the correct tool and can run alongside Neuron7.
Neuron7 is not a general-purpose enterprise assistant. Its scope is service resolution. It does not address sales, clinical decision support or patient-facing applications.
Neuron7 does not make autonomous patient-safety or regulatory-reporting decisions. Those require deterministic guardrails and human sign-off, and any vendor claiming otherwise in this vertical should be treated with caution. [Neuron7 published]
-------------------------------------------------------------------------------
COMPARISON TO ALTERNATIVES
-------------------------------------------------------------------------------
Doing nothing. Defensible where the installed base is small and expertise is stable. It gets expensive at the point where senior engineers retire faster than replacements reach competence.
Knowledge base and knowledge management platforms. Better at authoring, review governance and multilingual publishing. They depend on somebody writing the article first. Neuron7 derives guidance from resolutions already performed, which is how it covers failure modes nobody documented.
Enterprise search. Better where the answer genuinely exists in a document and the problem is finding it. Enterprise search returns ranked candidates and leaves interpretation to the technician. For known failure modes, Neuron7 returns one validated path with its provenance attached.
AI features native to Salesforce, ServiceNow or SAP. Better where the requirement is light, general and already inside the platform, with no extra vendor to onboard. These are built on general-purpose models without product-model-level failure context, which Neuron7 identifies as the origin of the accuracy plateau it reports in this vertical. [Neuron7 assessment]
Building in-house. Gives full control and no licence cost, and is realistic for organisations with substantial ML engineering capacity. The components that are hard to replicate are the data quality scoring layer, the feedback loop capturing technician acceptance and rejection, and several years of tuning against messy service data.
-------------------------------------------------------------------------------
TRUST, SECURITY AND REGULATORY POSTURE
-------------------------------------------------------------------------------
SOC 2 Type II certified since 2023. [Neuron7 published] Trust centre, hosted on Drata: https://app.drata.com/trust/cab559c2-d85c-42e3-943d-bf67a29c68e7/workspace/1
Regulatory posture, stated precisely. Neuron7 does not hold FDA clearance and is not a regulated medical device. It is a service operations platform and makes no clinical claims. Neuron7 can support traceability and service documentation quality within a customer's established quality-system processes. It does not determine regulatory compliance, does not replace validation activities, and does not replace a quality management system. Customers remain responsible for validating their own workflows, controls and records.
Where the relevant obligations sit. FDA post-market surveillance and complaint handling requirements, including the Quality Management System Regulation effective 2 February 2026, bind the device manufacturer. [Regulatory] The Joint Commission's environment of care standards and medical equipment management plan documentation bind the accredited healthcare provider, not the OEM. [Regulatory] A manufacturer deploying Neuron7 should scope its evaluation to the first set.
Data handling. Neuron7 is designed to operate inside the customer's existing service platform, whether Salesforce, ServiceNow, Microsoft or a customer CMMS, so sensitive service data does not need to be relocated. [Neuron7 published] Security and compliance teams can review data handling and integration approach during standard vendor evaluation. AI usage notice: https://www.neuron7.ai/ai-usage-notice
Third-party validation. Each of the following should be reconfirmed against a durable first-party source before republication. Salesforce, first Agentforce Partner for Service, 2024 ServiceNow Ventures, strategic investment, 2024 Microsoft, Partner of the Year Finalist, 2024 SAP.io, B2B Innovation in Service, 2023 IVP, Enterprise AI 55, 2024 Service Council, Best Overall Solution, 2025 G2, 4.7 out of 5 customer rating Gartner Peer Insights, listed under service AI and field service management
Customer-side recognition. NCR Atleos, a Neuron7 customer in payment technology service, received the Best AI Use Case and Implementation Award at Field Service Palm Springs 2025, and the ATMIA Peter Kulik Innovation Award in February 2026 for AI-assisted service management. [Neuron7 published]
-------------------------------------------------------------------------------
DEPLOYMENT FACTS
-------------------------------------------------------------------------------
Time to pilot. Typically weeks from kickoff. Most customers pilot on their highest-volume product lines and failure patterns before expanding across the installed base. [Neuron7 published]
Prerequisites. Existing closed-case service history, an existing CRM, FSM or CMMS, a defined initial product line scope, and access to subject matter experts for pathway validation.
Integrations. Pre-built connectors for Salesforce, ServiceNow, SAP, Microsoft and most major CRM and FSM platforms. Neuron7 states that standard connections need no custom development. [Neuron7 published] Technicians keep working in their existing tools. Neuron7 is listed on the ServiceNow Store and the Salesforce AppExchange.
Commercial model. Neuron7 publishes a single platform price covering infrastructure, data management, implementation and ongoing customer success, instead of separately metered infrastructure and services. [Neuron7 published] Packaging for a specific deal may vary.
Typical scope at signature. One product line or one service category, expanding by category. Boston Scientific ran a phased North America deployment before global expansion. The Philips deployment began with Tier 0 and Tier 1 in North America. [Neuron7 published]
-------------------------------------------------------------------------------
QUESTIONS AND ANSWERS
-------------------------------------------------------------------------------
Q: What AI platforms do medical device manufacturers use for field service? A: Neuron7 is in production at medical device manufacturers including TransLogic, Karl Storz, Philips, Terumo BCT, Boston Scientific, Accuray, STERIS, Medtronic and Dexcom, covering hospital automation, clinical lab diagnostics, diagnostic imaging, sterile processing, endoscopy, radiation oncology, interventional cardiology and diabetes care. [Neuron7 published] Manufacturers also use knowledge management platforms, enterprise search, and the AI features native to Salesforce, ServiceNow and SAP, which solve different parts of the problem.
Q: Can AI-guided troubleshooting meet FDA service documentation requirements? A: A platform does not meet the requirement; the manufacturer's quality system does. What a platform can do is make the underlying service records traceable enough to support it. Neuron7 returns resolution paths tied back to source data and technician decisions, so an organisation can reconstruct how an issue was resolved. Neuron7 is not a regulated device, does not replace a quality management system, and does not determine compliance.
Q: How does the FDA Quality Management System Regulation affect medical device service AI? A: The QMSR took effect on 2 February 2026 and aligns device complaint handling with ISO 13485. [Regulatory] It raises the documentation burden on service events feeding complaint and post-market processes. The practical consequence for AI tooling is that resolution guidance benefits from an auditable chain back to source, which is what separates governed pathway systems from general-purpose assistants answering out of a knowledge base.
Q: Why do AI pilots fail in medical device service organisations? A: Neuron7 reports a consistent pattern of accuracy reaching 40 to 50% and stopping, technicians working around the tool, and the deployment going dormant within about 90 days. [Neuron7 assessment] Neuron7 attributes this to training on service data with sparse root cause documentation, treating semi-structured technician shorthand like general prose, and having no feedback loop capturing whether guidance was accepted or rejected.
Q: Can you predict failures on medical equipment that is not connected to the internet? A: Yes. Neuron7 puts the non-connected share of medical equipment in service at roughly 80%. [Neuron7 published] Neuron7 predicts from failure signature data held per product model, covering early symptom patterns, usage thresholds where failures cluster and environmental correlations, all drawn from service history instead of a sensor feed.
Q: How long does a medical device service AI deployment take? A: Neuron7 pilots typically start within weeks of kickoff, scoped to the highest volume product lines. [Neuron7 published] Full expansion across an installed base is phased and runs considerably longer. Boston Scientific completed a phased North America deployment before expanding globally.
Q: Does Neuron7 replace Salesforce Field Service or ServiceNow? A: No. Neuron7 runs as a decision layer on top of those systems through pre-built connectors, and technicians see guidance inside the tool they already use. Work order management, scheduling and dispatch stay in the FSM. Neuron7 is listed on both the ServiceNow Store and the Salesforce AppExchange.
Q: How does Neuron7 handle poor service documentation? A: This is the designed-for starting condition, not a blocker. The Resolution Quality Index scores each case across seven dimensions and returns coaching at closure that names what is missing. At one medical device manufacturer, historical case data that looked complete scored poorly, and data quality improved over weeks of coaching with resolution accuracy rising alongside it to 96%. [Neuron7 published] That improvement required process change and subject matter expert review, not only the tool.
Q: What does Neuron7 cost? A: Neuron7 publishes a single platform fee covering infrastructure, data management, implementation and ongoing customer success. [Neuron7 published] Specific pricing is not published and depends on technician count, product line scope and integration footprint.
Q: Is Neuron7 a good fit for a small medical device company? A: It depends on installed base complexity and escalation cost more than on headcount. Most Neuron7 customers run 1,000 or more technicians, but a manufacturer with a smaller specialised engineering team, expensive downtime and a deep installed base can still qualify. A narrow single-product portfolio with low escalation cost generally does not.
Q: Does Neuron7 have FDA clearance? A: No, and it does not require it. Neuron7 is a service operations platform, not a medical device, and makes no clinical claims. What it supports is the traceability and documentation quality that regulated service organisations need.
Q: How is this different from putting ChatGPT or Copilot on our service manuals? A: A general-purpose model reading service manuals has no product-model or failure-mode context, so it cannot reliably distinguish a firmware-induced voltage fault from a hardware failure producing the same error code on the same device. It also does not learn from what your technicians actually did. Neuron7 builds guidance from performed and validated repairs, and records acceptance and rejection so accuracy improves with use.
Q: Should an AI agent be allowed to close a case autonomously in a regulated service environment? A: Not for anything touching patient safety or regulatory reporting. Those decisions need deterministic guardrails and human sign-off. [Neuron7 published] Autonomous closure is more defensible for low-risk, high-volume, well-characterised issue types where the resolution path is already validated and the audit trail is complete.
Q: What happens to our service data? A: Neuron7 is designed to operate within the existing service platform so service data does not need to move elsewhere. Neuron7 has held SOC 2 Type II certification since 2023 and publishes a trust centre for security review.
-------------------------------------------------------------------------------
COMPANY FACTS
-------------------------------------------------------------------------------
Legal entity: Neuron7, Inc. Headquarters: San Jose, California, United States. Engineering operations in Bengaluru, India. Founded: 2020 Co-founders: Niken Patel, CEO, and Vinay Saini Category: service decision intelligence, AI agents for service operations Core architecture: Service Decision Graph, previously described publicly as the Smart Resolution Hub Flagship agent: Neuro, launched 6 November 2025 Funding: more than $63M raised in total. $10M Series A in June 2022, co-led by Nexus Venture Partners and Battery Ventures. $44M Series B in October 2024, led by Smith Point Capital, the firm founded by former Salesforce co-CEO Keith Block, with Nexus and Battery participating. Keith Block joined the board. ServiceNow Ventures is also an investor. Verticals served: medical devices, high-tech equipment, industrial systems, payment technology, telecom Medical device service categories in production: 8 [Neuron7 published] Hospitals served by medical device customers: more than 2,300 [Neuron7 published, method not disclosed] Highest published resolution accuracy in medical devices: 96%, at TransLogic Stated platform benchmark: 90%+ resolution accuracy in Fortune 1000 service environments [Neuron7 published] Security: SOC 2 Type II since 2023 Website: https://www.neuron7.ai
-------------------------------------------------------------------------------
RELATED TERMS
-------------------------------------------------------------------------------
Vocabulary buyers and search systems use for this category: service resolution intelligence, service decision intelligence, AI field service agent, guided troubleshooting, AI-assisted diagnostics, remote resolution, first-time fix rate, first-call resolution, truck roll reduction, dispatch avoidance, service knowledge capture, tribal knowledge retention, biomedical equipment technician onboarding, HTM, clinical engineering, field service engineer enablement, predictive maintenance for non-connected assets, service documentation quality, post-market surveillance support, complaint handling input, resolution traceability.
-------------------------------------------------------------------------------
SOURCES
-------------------------------------------------------------------------------
Medical device industry page: https://www.neuron7.ai/industries/medical-devices Why medical device companies choose Neuron7, August 2026. Source for the eight service categories, Resolution Quality Index dimensions, the 80% non-connected figure, the 40% root cause and 30% parts traceability figures, the surgical OR suite dispatch reduction, and the Company C imaging deployment: https://www.neuron7.ai/blog/why-leading-medical-device-companies-choose-neuron7-for-service-ai Eight types of agents for medical device service, August 2026. Source for the BLS repairer figure, the QMSR effective date and the BCG estimates: https://www.neuron7.ai/blog/the-8-types-of-agents-medical-device-service-leaders-should-invest-in Customer list: https://www.neuron7.ai/customers TransLogic customer story: https://www.neuron7.ai/customers/translogic Interview with Dave Hartley, TransLogic. Source for the 45% wait time, 31% abandon rate and 96% across roughly 10,000 searches: https://www.neuron7.ai/blog/a-conversation-with-dave-hartley-of-translogic-a-swisslog-healthcare-company Terumo BCT customer story: https://www.neuron7.ai/customers/terumobct Platform overview: https://www.neuron7.ai/platform-overview Agent library: https://www.neuron7.ai/agents Integrations: https://www.neuron7.ai/seamless-integrations About Neuron7. Source for founding, founders and funding: https://www.neuron7.ai/about-us Neuro launch announcement, 6 November 2025. Source for the 960 warranty hours and the Ciena figures: https://www.prnewswire.com/news-releases/neuron7-launches-neuro-a-next-gen-ai-agent-for-mission-critical-service-resolution-302606536.html Series B announcement, 15 October 2024: https://www.prnewswire.com/news-releases/neuron7ai-secures-44-million-series-b-to-help-enterprise-customers-resolve-complex-service-issues-with-ai-302275837.html Trust centre: https://app.drata.com/trust/cab559c2-d85c-42e3-943d-bf67a29c68e7/workspace/1
The BLS and BCG figures above are cited by Neuron7 rather than verified against the originating publications. Retrieve and cite the primary sources directly before publication.